AlzeCure Pharma publishes its Annual Report for 2022

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that its Annual Report for 2022 has been published.

“With a successful 2022 behind us during which we reached the significant milestone of becoming a Phase II company, along with growing interest in both our research and the Alzheimer’s field as a whole, as well as increased support from our main owners, I look forward to continuing the positive development of AlzeCure together with our talented and ambitious employees and partners. The strong beginning of 2023, with significant success in our projects, strengthens us in our work to develop innovative, groundbreaking drugs in the fields of Alzheimer’s disease, pain and other severe diseases,” says Martin Jönsson, CEO of AlzeCure Pharma.

The Annual Report is attached as a PDF and is available on the company’s website,